Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Net assets


Fully diluted NAV per share


NAV total return


Capital pool available to invest in life science


New companies formed in 2019


Proceeds from the sale of Nightstar


FY2020 Outlook

  • Sales and earnings growth in Blue Earth
  • Strong progress in our clinical pipeline, including high impact data read outs
  • New company formations and financings; capital deployment of £100-200m